SUMMIT, N.J., July 9, 2024 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), today announced that it has commenced shipping its differentiated portfolio of influenza vaccines. This year, the ...
CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results